IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Vilin Bio Med IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Secunderabad and caters to Pharmaceutical sector. Inventure Merchant Banker Services Private is the merchant banker of Vilin Bio Med IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 28th March 2023.
Vilin Bio Med IPO posted revenues of Rs 12.04 crores and PAT of Rs 1.71 crores in FY23 on annualised basis.Financial results of Vilin Bio Med IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Vilin Bio Med IPO PAT Margin is 14.21%, ROCE (Return on Capital Employed) is 8.58% as per latest financial. The below table shows Vilin Bio Med IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Vilin Bio Med IPO is Rs 41.85 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Vilin Bio Med IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Vilin Bio Med IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Vilin Bio Med IPO is ₹41.85 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Vilin Bio Med IPO has a Price-to-Earnings (PE) ratio of 24.59 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Vilin Bio Med IPO reported revenue of ₹12.04 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Vilin Bio Med IPO provide insights into sales growth, market demand, and business scalability.
Vilin Bio Med recorded an EBITDA of ₹ 3.13 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Vilin Bio Med Profit After Tax (PAT) is ₹1.71 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 12.01 Cr.
EBITDA Margin:
26.08
%
Net Worth: ₹ 8.67 Cr.
Market Capitalisation:
₹ 41.85 Cr.
P/E:
24.59 times
P/BV: 2.02 times
EV/EBITDA: 15.32 times
Vilin Bio Med operates in Pharmaceutical and Manufacturing Pharmaceuticals Products. The Issue is listed on NSE EMERGE in Jun, 2023. Vilin Bio Med IPO size was 12.00 with Issue price of 30.00 .
Merchant Banker(s) of Vilin Bio Med IPO: Inventure Merchant Banker Services Private Limited
Vilin Bio Med IPO subscription was 2.80 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Vilin Bio Med IPO listed at a listing price of 30.00 against the offer price of 30.00.
The current market price of Vilin Bio Med is 26.85.
Why Us?
